Drug Trial Radar · NCT06013241
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
288
Actual
Start
Oct 30, 2023
Primary completion
Sep 30, 2025
Study completion Oct 30, 2025
Sponsor
- Lead sponsor
- Insmed IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Aug 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.
Conditions
- Chronic Rhinosinusitis Without Nasal Polyps
Interventions
BrensocatibDrug
Film-coated tablet.
PlaceboDrug
Film-coated tablet.
Mometasone furoate nasal spray (MFNS)Drug
Nasal spray suspension.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to the 28-day Average of Daily Sinus Total Symptom Score (sTSS) at Week 24Time frame: Baseline and Week 24
Locations
100 sites in 15 countries. Site status is shown where the registry gives one.
USA034
Tucson, Arizona
USA002
Roseville, California
USA006
Upland, California
USA016
Boca Raton, Florida
USA019
Hollywood, Florida
USA001
Miami, Florida
USA009
Tampa, Florida
USA031
Chicago, Illinois
USA021
Chicago, Illinois
USA003
New Albany, Indiana
USA035
Mandeville, Louisiana
USA026
Baltimore, Maryland
USA011
Columbia, Missouri
USA024
St Louis, Missouri
USA033
New York, New York
USA028
Tulsa, Oklahoma
USA004
Tulsa, Oklahoma
USA015
Hershey, Pennsylvania
USA023
Charleston, South Carolina
USA022
North Charleston, South Carolina
USA025
Dallas, Texas
USA037
Fredericksburg, Texas
USA029
Houston, Texas
USA018
Houston, Texas
USA030
San Antonio, Texas
USA038
Tomball, Texas
USA005
Norfolk, Virginia
ARG002
Mar del Plata, Argentina
ARG014
Mendoza, Argentina
ARG003
Mendoza, Argentina
ARG016
Rosario, Argentina
ARG008
Santa Fe, Argentina
ARG015
La Plata, Buenos Aires, Argentina
ARG001
La Plata, Buenos Aires, Argentina
ARG006
Lobos, Buenos Aires, Argentina
ARG005
Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina
ARG012
Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina
ARG011
Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina
ARG017
Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina
ARG013
San Rafael, Mendoza Province, Argentina
Showing 40 of 100 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.